These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Schizophrenia: gender, family risk, and plasma homovanillic acid. Dávila R; Zumárraga M; González-Torres MA; Andía I; Zamalloa MI; Basterreche E; Guimón J; Friedhoff AJ Am J Med Genet; 1995 Apr; 60(2):154-6. PubMed ID: 7485251 [TBL] [Abstract][Full Text] [Related]
23. Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Kaminski R; Powchick P; Warne PA; Goldstein M; McQueeney RT; Davidson M Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(3):271-87. PubMed ID: 2193315 [TBL] [Abstract][Full Text] [Related]
24. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis. Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672 [TBL] [Abstract][Full Text] [Related]
25. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance. Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375 [TBL] [Abstract][Full Text] [Related]
26. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited. Volavka J; Douyon R; Convit A; Czobor P; Cooper TB Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388 [No Abstract] [Full Text] [Related]
27. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. Davidson M; Giordani AB; Mohs RC; Horvath TB; Davis BM; Powchik P; Davis KL Arch Gen Psychiatry; 1987 Feb; 44(2):189-90. PubMed ID: 3813816 [No Abstract] [Full Text] [Related]
28. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541 [TBL] [Abstract][Full Text] [Related]
29. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579 [TBL] [Abstract][Full Text] [Related]
30. Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease. Rose S; Hindmarsh JG; Steiger MJ; Bhatt M; Quinn NP; Jenner P; Marsden CD Clin Neuropharmacol; 1994 Jun; 17(3):260-9. PubMed ID: 9316671 [TBL] [Abstract][Full Text] [Related]
31. GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients. Arrúe A; Dávila R; Zumárraga M; Basterreche N; González-Torres MA; Goienetxea B; Zamalloa MI; Anguiano JB; Guimón J Neurochem Res; 2010 Feb; 35(2):247-53. PubMed ID: 19701707 [TBL] [Abstract][Full Text] [Related]
32. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period. Sharma RP; Javaid JI; Davis JM; Janicak PG Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181 [TBL] [Abstract][Full Text] [Related]
33. Effects of single dose haloperidol administration on plasma homovanillic acid levels in normal subjects. Magliozzi JR; Doran AR; Gietzen DW; Olson AM; Maclin EL; Tuason VB Psychiatry Res; 1993 May; 47(2):141-9. PubMed ID: 8341767 [TBL] [Abstract][Full Text] [Related]
34. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918 [TBL] [Abstract][Full Text] [Related]
35. Plasma homovanillic acid levels and subtyping of schizophrenia. Chang WH; Chen TY; Lee CF; Hung JC; Hu WH; Yeh EK Psychiatry Res; 1988 Mar; 23(3):239-44. PubMed ID: 3387499 [TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942 [TBL] [Abstract][Full Text] [Related]
37. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia. Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567 [TBL] [Abstract][Full Text] [Related]
38. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients. Zumárraga M; Dávila R; González-Torres MA; Anguiano JB; Zabalo MJ; Basterreche N; Arrúe A; Zamalloa MI; Guimón J Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):713-9. PubMed ID: 17291661 [TBL] [Abstract][Full Text] [Related]
39. Plasma homovanillic acid concentration and the severity of schizophrenic illness. Davis KL; Davidson M; Mohs RC; Kendler KS; Davis BM; Johns CA; DeNigris Y; Horvath TB Science; 1985 Mar; 227(4694):1601-2. PubMed ID: 3975630 [TBL] [Abstract][Full Text] [Related]
40. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Aymard N; Viala A; Stein I; Caroli F Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]